Blood Product (Donor) Noninfectious and Infectious Testing and Modification.

Blood transfusion begins with safe donor selection and testing. In the United States, the blood supply and transfusion are highly regulated. Blood transfusion safety is multifaceted, whereby each of the elements of the blood safety value chain, spanning donor recruitment and qualification, to collection, blood processing, testing, transfusion practice, and posttransfusion surveillance, must be optimized to minimize risk. Pathogen inactivation is a promising approach to decrease bacterial contamination of platelets, inactivate parasites and viruses, and decrease risks associated with emerging and unidentified pathogens. This article offers an overview of blood donor infectious and noninfectious testing in the United States.

• Publication year

  2021

• Venue

  Clinics in Laboratory Medicine

• Publication date

  2021-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cll.2021.07.002PMID 34689966
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12‐month deferral policy for men who have sex with men

  2021cited by this paper
• Secondary bacterial culture of platelets to mitigate transfusion‐associated sepsis: A 3‐year analysis at a large academic institution

  2020cited by this paper
• No evidence of transfusion transmitted sporadic Creutzfeldt‐Jakob disease: results from a bi‐national cohort study

  2020cited by this paper
• Persistence of Babesia microti Infection in Humans

  2019cited by this paper
• Pathogen Reduction: The State of the Science in 2019.

  2019cited by this paper
• Prevention of transfusion-transmitted infections.

  2019cited by this paper
• Assessing the risk of Babesia to the United States blood supply using a risk‐based decision‐making approach: Report of AABB's Ad Hoc Babesia Policy Working Group (original report)

  2018cited by this paper
• Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)

  2018cited by this paper
• Transfusion-Transmitted Infections: an Update on Product Screening, Diagnostic Techniques, and the Path Ahead

  2018cited by this paper
• An ultra-sensitive Abbott ARCHITECT® assay for the detection of hepatitis B virus surface antigen (HBsAg).

  2018cited by this paper
• Creutzfeldt‐Jakob disease and blood transfusion safety

  2018cited by this paper
• The epidemiology of bacterial culture–positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016

  2018cited by this paper
• Residual risk of bacterial contamination: what are the options?

  2017cited by this paper
• Inactivation of Babesia microti in red blood cells and platelet concentrates

  2017cited by this paper
• Creutzfeldt‐Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk

  2017cited by this paper
• Transfusion‐transmitted CMV infection – current knowledge and future perspectives

  2017cited by this paper
• Zika virus in the blood supply.

  2017cited by this paper
• Zika virus in asymptomatic blood donors in Martinique.

  2017cited by this paper
• Screening for Babesia microti in the U.S. Blood Supply.

  2016cited by this paper
• Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial.

  2016cited by this paper
• Zika Virus.

  2016cited by this paper
• Zika Virus Infection in Pregnant Women in Rio de Janeiro.

  2016cited by this paper
• Zika and the Risk of Microcephaly.

  2016cited by this paper
• Zika Virus Infection in Pregnant Women in Rio de Janeiro — Preliminary Report

  2016cited by this paper
• Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation.

  2016cited by this paper
• Transfusion-related sepsis: a silent epidemic.

  2016cited by this paper
• Zika Virus and Birth Defects--Reviewing the Evidence for Causality.

  2016cited by this paper
• Emerging Infections and Blood Safety in the 21st Century

  2016cited by this paper
• Screening of Blood Donations for Zika Virus Infection - Puerto Rico, April 3-June 11, 2016.

  2016cited by this paper
• Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance.

  2016cited by this paper
• Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature

  2015cited by this paper
• Keeping Blood Transfusion Safe From West Nile Virus: American Red Cross Experience, 2003 to 2012.

  2015cited by this paper
• Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation

  2015cited by this paper
• Infectious risks of blood transfusions: Recent advances in testing technologies and new approaches to surveillance and decision‐making

  2014cited by this paper
• Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014.

  2014cited by this paper
• Chapter 11 – Overview of Infectious Disease Testing

  2013cited by this paper
• The concept of “confirmatory testing” of donors for ABO and RhD

  2013cited by this paper
• A patient‐oriented risk–benefit analysis of pathogen‐inactivated blood components: application to apheresis platelets in the United States

  2013cited by this paper
• Age of red blood cells and transfusion in critically ill patients

  2013cited by this paper
• Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?

  2013cited by this paper
• International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009

  2012cited by this paper
• Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century

  2012cited by this paper
• Management and Prevention of Red Cell Alloimmunization in Pregnancy: A Systematic Review

  2012cited by this paper
• Nucleic acid testing to detect HBV infection in blood donors.

  2011cited by this paper
• Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress

  2010cited by this paper
• Duration of red cell storage before transfusion and in-hospital mortality.

  2010cited by this paper
• Direct assessment of cytomegalovirus transfusion‐transmitted risks after universal leukoreduction

  2010cited by this paper
• Survey of current practice for prevention of transfusion‐transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus‐seronegative

  2010cited by this paper
• Cost‐effectiveness of screening the US blood supply for Trypanosoma cruzi

  2010cited by this paper
• Prevalence, incidence, and residual risk of major blood‐borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008

  2010cited by this paper
• Current value of serologic test for syphilis as a surrogate marker for blood‐borne viral infections among blood donors in the United States

  2009cited by this paper
• Risk for malaria in United States donors deferred for travel to malaria‐endemic areas

  2009cited by this paper
• A test that won't die: the serologic test for syphilis

  2009cited by this paper
• Emerging infectious disease agents and their potential threat to transfusion safety

  2009cited by this paper
• TRANSFUSION COMPLICATIONS: Bacterial culture reduces but does not eliminate the risk of septic transfusion reactions to single‐donor platelets

  2009cited by this paper
• Transfusion-transmitted babesiosis in the United States: summary of a workshop.

  2009cited by this paper
• The hazards of blood transfusion in historical perspective.

  2008cited by this paper
• Transfusion transmission of human prion diseases.

  2008cited by this paper
• Return behavior of blood donors after expiration of a 1‐year malarial travel deferral

  2007cited by this paper
• Effectiveness of human T‐lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV‐I and ‐II confirmatory algorithm, 1999 to 2004

  2006cited by this paper
• Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.

  2005cited by this paper
• A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors

  2005cited by this paper
• Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.

  2004cited by this paper
• Transmission of West Nile virus through blood transfusion in the United States in 2002.

  2003cited by this paper
• US NAT yield: where are we after 2 years?

  2002cited by this paper
• The outbreak of West Nile virus infection in the New York City area in 1999.

  2001cited by this paper
• Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size

  1999cited by this paper
• The clinical relevance of HTLV type I and II in transfusion medicine.

  1997cited by this paper
• The clinical epidemiology of human T-lymphotropic virus type II (HTLV-II).

  1996cited by this paper
• The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.

  1996cited by this paper
• The Risk of Transfusion-Transmitted Viral Infections

  1996cited by this paper
• Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody

  1994cited by this paper
• Guidelines for Counseling Persons Infected with Human T-Lymphotropic Virus Type I (HTLV-I) and Type II (HTLV-II)

  1993cited by this paper
• Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective.

  1991cited by this paper
• Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV‐1 antibody screening

  1991cited by this paper
• Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

  1989cited by this paper
• Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood.

  1986cited by this paper
• Donor transaminase and recipient hepatitis. Impact on blood transfusion services.

  1981cited by this paper
• Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study.

  1981cited by this paper
• Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations.

  1970cited by this paper
• Transmission of Syphilis by Fresh Blood Components

  1969cited by this paper
• Emerging Blockininfectious Blockindiseases Blockin@bullet Blockin

  year unknowncited by this paper

• No citing papers are available for this paper.